Introduction
============

Breast cancer is the most common type of cancer in women, accounting for 25% of all cases ([@b1-ol-0-0-6779]). Risk factors include lifestyle (including smoking or diet), genetics and medical conditions. A number of treatment methods are now available for breast cancer, including surgery, radiotherapy, chemotherapy, hormone therapy and targeted therapy. However, certain patients have a poor prognosis and the molecular mechanisms underlying this remain unclear. Prognostic factors include disease stage and grade, recurrence of the disease, and the age and health of the patient.

With advances in technology and the accumulation of research results, certain molecular markers associated with breast cancer have been well studied. Tumor protein p53 mutations are poor prognostic factors in breast cancer ([@b2-ol-0-0-6779]). MYC proto-oncogene and bHLH transcription factor-driven accumulation of 2-hydroxyglutarate are associated with poor breast cancer prognosis ([@b3-ol-0-0-6779]). Prostaglandin-endoperoxide synthase 2 expression predicts worse breast cancer prognosis ([@b4-ol-0-0-6779]). Ki-67 has been associated with disease-free survival, but its prognostic value remains to be validated ([@b5-ol-0-0-6779]). Matrix metalloproteinase-8 gene variation may influence breast cancer prognosis and can have an inhibitory effect on cancer metastasis ([@b6-ol-0-0-6779]). A gene signature involved in tumor-immune interactions may provide a more accurate prognostic tool ([@b7-ol-0-0-6779]). Zhang *et al* ([@b8-ol-0-0-6779]) performed a meta-analysis and demonstrated that overexpression of C-X-C motif chemokine receptor 4 was significantly associated with lymph node status and distant metastasis, indicating poor overall and disease free survival. SRY-box 4 overexpression is a biomarker for malignant status and poor prognosis in breast cancer patients ([@b9-ol-0-0-6779]). A number of other novel biomarkers have also been also identified, including chromobox homolog 1 ([@b10-ol-0-0-6779]), HOX transcript antisense intergenic RNA ([@b9-ol-0-0-6779]) and anterior gradient 3 ([@b11-ol-0-0-6779]). Nevertheless, more prognostic genes are required to further improve treatment decisions and thus the quality of life of patients with breast cancer.

Microarray technology has been widely used to identify biomarkers of breast cancer ([@b12-ol-0-0-6779],[@b13-ol-0-0-6779]), allowing for the large-scale screening of molecular markers. In the present study, two gene expression datasets were obtained to reveal prognostic genes ([@b14-ol-0-0-6779],[@b15-ol-0-0-6779]). One dataset was used with the aim of identifying genes associated with the distant metastasis of lymph-node-negative primary breast cancer ([@b14-ol-0-0-6779]); the other was used to identify genes involved in response and survival following taxane-anthracycline chemotherapy in breast cancer ([@b14-ol-0-0-6779]). The two datasets were combined to construct a gene co-expression network and analyze survival time to identify novel biomarkers associated with breast cancer prognosis.

Materials and methods
=====================

### Raw data and pre-treatment

Two gene expression datasets, GSE2034 ([@b14-ol-0-0-6779]) and GSE25066 ([@b15-ol-0-0-6779]), were downloaded from ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>). Dataset GSE2034 included 286 breast cancer samples and dataset GSE25066 included 508 breast cancer samples. The two gene expression datasets were obtained using Affymetrix GPL96 platform.

Normalization was performed with rma from the affy package ([@b16-ol-0-0-6779]) in R (R 3.2.0; <https://www.r-project.org/>) and then log~2~ conversion was applied. Probes were mapped onto genes according to annotation files. Probes mapping to the same gene were averaged as the expression level for the gene.

### Functional enrichment analysis

Gene Ontology (GO) annotation and pathway enrichment analysis were performed with DAVID (Database for Annotation, Visualization and Integration Discovery; <http://david.abcc.ncifcrf.gov/>) ([@b17-ol-0-0-6779]).

### Gene co-expression network and modules

The gene co-expression network was constructed with the WGCNA package ([@b18-ol-0-0-6779]) in R. The adjacency coefficient *a~ij~* was calculated as follows:
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Where *x~i~* and *x~j~* are vectors of expression value for gene *i* and *j*; cor represents the Pearson\'s correlation coefficient of the two vectors; *a~ij~* is the adjacency coefficient and is acquired via exponential transform of *S~ij~*.

WGCNA method takes topological properties into consideration to identify modules from gene co-expression networks. Therefore, this method not only considers the association between the two connected nodes, but also takes associated genes into account. It calculates the weighting coefficient *W~ij~* from *a~ij~* as follows:
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*W~ij~* considers the overlap between neighbor genes of genes *i* and *j*. Modules were identified via hierarchical clustering of the weighting coefficient matrix, *W*.

### Survival analysis

Cox regression was performed with hub genes from the modules to identify survival-associated genes, and Kaplan-Meier survival was used to compare the survival time of different groups, which were performed with the Survival package in R (<https://cran.r-project.org/web/views/Survival.html>). P\<0.05 was considered to indicate a statistically significant difference. Pearson\'s correlation was performed by cor function in R ([@b19-ol-0-0-6779]).

Results
=======

### Gene expression data

A total of 13,191 genes were identified in the GSE2034 and GSE25066 datasets, for which box plots are presented in [Fig. 1](#f1-ol-0-0-6779){ref-type="fig"}. According to the box plots, the average total mRNA expression level in each sample was consistent, indicating that a good performance of normalization was achieved for both datasets.

### Functional enrichment analysis

A total of 2,669 genes with coefficient of variation (CV) \>0.5 were selected. Functional enrichment analysis revealed that they were associated primarily with immune response, cell proliferation, cell differentiation and cell adhesion ([Table I](#tI-ol-0-0-6779){ref-type="table"}).

### Prognostic genes

Two gene co-expression networks were constructed for the two datasets by WGCNA ([Fig. 2](#f2-ol-0-0-6779){ref-type="fig"}). Seven modules were identified from the network of GSE2034 via hierarchical clustering of the weighting coefficient matrix, *W* ([Fig. 3](#f3-ol-0-0-6779){ref-type="fig"}). The modules were termed the red, blue, green, black, brown, yellow and turquoise modules.

The degree, *k*, for each gene in the module was calculated and the P-value of Cox regression between each gene and survival was also determined. Next, the correlation between *k* and -log~10~ (P) was calculated. The yellow module exhibited significant correlation with survival time in dataset GSE2034 (P=9.3×10^−13^) ([Fig. 4A](#f4-ol-0-0-6779){ref-type="fig"}), which was also observed in dataset GSE25066 (P=9.3×10^−6^) ([Fig. 4B](#f4-ol-0-0-6779){ref-type="fig"}). Besides, survival-associated genes (P\<0.05 in Cox regression) were significantly over-represented in the yellow module in both datasets ([Fig. 5](#f5-ol-0-0-6779){ref-type="fig"}). Therefore, the yellow module was considered to be significantly associated with breast cancer patient survival, which should be further investigated to understand the association between survival time and critical gene expression.

The 144 genes from the yellow module were used in the cluster analysis of samples from dataset GSE2034, which separated the patient samples into two groups based on the expression of these genes ([Fig. 6](#f6-ol-0-0-6779){ref-type="fig"}). A significant difference in survival time was observed between the two groups (P=0.008; [Fig. 7](#f7-ol-0-0-6779){ref-type="fig"}). Functional enrichment analysis indicated that the 144 genes from the yellow module were involved in cell cycle, oocyte meiosis, the tumor protein p53 signaling pathway and progesterone-mediated oocyte maturation ([Table II](#tII-ol-0-0-6779){ref-type="table"}).

The top 10 hub genes from the yellow module were selected ([Table III](#tIII-ol-0-0-6779){ref-type="table"}) and included cyclin B2 (CCNB2), ubiquitin-conjugating enzyme E2C (UBE2C), protein regulator of cytokinesis 1 (PRC1), cell division cycle 20 (CDC20), abnormal spindle microtubule assembly (ASPM), forkhead box M1 (FOXM1), kinesin family member 4A (KIF4A), nucleolar and spindle associated protein 1 (NUSAP1), pituitary tumor-transforming 1 (PTTG1) and centrosomal protein 55 kDa (CEP55). All of these genes were significantly associated with survival time in the two datasets.

Discussion
==========

Two gene expression datasets of breast cancer were obtained and the 2,669 differentially expressed genes with a CV \>0.5 were selected. These genes were implicated in the immune response, cell proliferation and cell migration. These functions were closely associated with the development and metastasis of cancer. A breast-cancer-specific gene co-expression network was constructed for dataset GSE2034, from which 7 modules were identified. The yellow module was closely associated with survival time and, as such, the 144 genes from yellow module were investigated further. These genes were primarily involved in the cell cycle and tumor protein p53 signaling pathway. The top 10 hub genes were identified in the yellow module, all of which were associated with poor patient prognosis.

The majority of the 10 critical genes in the yellow module are associated with the cell cycle. CCNB2 is an essential component of the cell-cycle regulatory machinery ([@b20-ol-0-0-6779]). Elevated CCNB2 expression in invasive breast cancer is associated with unfavorable clinical outcomes ([@b21-ol-0-0-6779]). UBE2C is required for the degradation of mitotic cyclins and for cell-cycle progression, and is involved in cancer progression. UBE2C is highly expressed in breast microcalcification lesions ([@b22-ol-0-0-6779]). The prognostic value of UBE2C has been validated in several studies ([@b23-ol-0-0-6779]--[@b25-ol-0-0-6779]). microRNA-196a post-transcriptionally upregulates UBE2C and promotes cell proliferation in breast cancer ([@b26-ol-0-0-6779]). Inhibition of UBE2C reduces proliferation and sensitizes breast cancer cells to radiotherapy and chemotherapy ([@b27-ol-0-0-6779]), suggesting that it could serve as a potential therapeutic target. CDC20 is a regulatory protein in the cell cycle. Overexpression of CDC20 predicts short-term breast cancer survival ([@b22-ol-0-0-6779]). ASPM is essential for normal mitotic spindle function and is a marker for vascular invasion, early recurrence and poor prognosis of hepatocellular carcinoma ([@b28-ol-0-0-6779]). Increased ASPM expression is also associated with enhanced tumor grade and lower survival rates of epithelial ovarian cancer ([@b29-ol-0-0-6779]). A significant correlation between the expression of the CCNB2 and ASPM proteins is reported ([@b21-ol-0-0-6779]), which may serve a role in the development of breast cancer.

FOXM1 is a transcriptional activator involved in cell proliferation, which is a downstream target and marker of HER2 overexpression in breast cancer ([@b30-ol-0-0-6779]). FOXM1 is implicated in the proliferation, migration and invasion of breast cancer cells ([@b31-ol-0-0-6779],[@b32-ol-0-0-6779]) and serves a role in chemotherapy resistance ([@b33-ol-0-0-6779],[@b34-ol-0-0-6779]). KIF4A is an ATP-dependent microtubule-based motor protein that is involved in the intracellular transport of membranous organelles. KIF4A is implicated in doxorubicin-induced apoptosis in breast cancer cells ([@b35-ol-0-0-6779]). NUSAP1 may be involved in tumorigenesis and in the processes of invasion and progression of breast cancer ([@b36-ol-0-0-6779]); it influences the DNA damage response by controlling the protein levels of BRCA1 ([@b37-ol-0-0-6779]). PTTG1 exhibits tumorigenic activity *in vivo* and is highly expressed in various tumors; it is associated with endocrine therapy resistance in breast cancer ([@b38-ol-0-0-6779]). PTTG1 may promote tumor malignancy via the epithelial-to-mesenchymal transition and the expansion of the cancer stem cell population ([@b39-ol-0-0-6779]). CEP55 is also involved in breast cancer progression ([@b40-ol-0-0-6779]), possibly exerting an oncogenic function via regulation of the phosphoinositide-3 kinase/protein kinase B pathway and midbody fate ([@b41-ol-0-0-6779]).

PRC1 encodes a protein involved in cytokinesis, specifically the polarization of parallel microtubules, whose expression level changes markedly in the different phases of the cell cycle. PRC1 has been demonstrated to be a substrate of several cyclin-dependent kinases (CDKs); its alternative splicing results in multiple transcript variants ([@b42-ol-0-0-6779],[@b43-ol-0-0-6779]). Although PRC1 serves an important role in the cell cycle, its role in breast cancer remains unclear. The results of the present study indicate that the role of PRC1 in the pathogenesis of breast cancer necessitates further study.

Gene co-expression network analysis revealed several genes of prognostic significance in breast cancer. The majority of these genes have been validated by previous studies; however, the function of certain critical genes identified by gene co-expression network analysis in breast cancer remains unclear, thus providing targets for further studies. These prospective studied may disclose novel biomarkers or provide targets for breast cancer therapies.

![Box plots of normalized gene expression data of two datasets. (A) GSE2034 (286 samples) and (B) GSE25066 (200 samples randomly selected from the total 508 samples). The average total mRNA expression level in each sample was consistent, indicating that a good performance of normalization was achieved. The x-axis represents the gene expression level; the y-axis represents the samples.](ol-14-04-4535-g02){#f1-ol-0-0-6779}

![Gene co-expression networks for datasets GSE2034 (left) and GSE25066 (right). The x-axis represents the degree of the node, *k*, while the y-axis represents proportion of genes with degree of *k*, *p (k)*.](ol-14-04-4535-g03){#f2-ol-0-0-6779}

![Seven modules identified from the gene co-expression network. Cluster analysis result is shown above and module identification shown below.](ol-14-04-4535-g04){#f3-ol-0-0-6779}

![Scatter plots of the degree and P-value of Cox regression in datasets (A) GSE2034 and (B) GSE25066. The x-axis indicates the degree of regression, the y-axis indicates the P-value. Each circle represents a gene.](ol-14-04-4535-g05){#f4-ol-0-0-6779}

![Survival-associated genes in each module. The x-axis indicates the module, the y-axis indicates the significance of over-representation.](ol-14-04-4535-g06){#f5-ol-0-0-6779}

![Cluster analysis using the degree of expression of 144 survival-associated genes for the samples in the GSE2034 dataset.](ol-14-04-4535-g07){#f6-ol-0-0-6779}

![Survival curves for the two groups of breast cancer patient samples clustered according to expression of the 144 genes.](ol-14-04-4535-g08){#f7-ol-0-0-6779}

###### 

Top 15 significantly over-represented biological pathways.

  ID           Description                                   P-value        Adjusted P-value
  ------------ --------------------------------------------- -------------- ------------------
  GO:0006955   Immune response                               2.19×10^−63^   3.27×10^−61^
  GO:0006952   Defense response                              2.15×10^−57^   2.80×10^−55^
  GO:0006950   Response to stress                            1.57×10^−56^   1.96×10^−54^
  GO:0007166   Cell-surface receptor signaling pathway       1.20×10^−55^   1.43×10^−53^
  GO:0008283   Cell proliferation                            1.06×10^−49^   1.09×10^−47^
  GO:0002682   Regulation of immune system process           6.12×10^−42^   4.82×10^−40^
  GO:0016477   Cell migration                                7.58×10^−40^   5.66×10^−38^
  GO:0045321   Leukocyte activation                          1.90×10^−39^   1.32×10^−37^
  GO:0006954   Inflammatory response                         3.92×10^−38^   2.66×10^−36^
  GO:0048584   Positive regulation of response to stimulus   6.10×10^−38^   4.05×10^−36^
  GO:0042127   Regulation of cell proliferation              1.72×10^−37^   1.10×10^−35^
  GO:0030154   Cell differentiation                          3.01×10^−34^   1.70×10^−32^
  GO:0048869   Cellular developmental process                2.06×10^−33^   1.14×10^−31^
  GO:0007155   Cell adhesion                                 7.77×10^−33^   4.22×10^−31^
  GO:0022610   Biological adhesion                           1.11×10^−32^   5.90×10^−31^

Adjusted P-value: Use the multiple comparisons in General Linear Model ANOVA, the adjusted P-value indicates which factor level comparisons within a family of comparisons (hypothesis tests) are significantly different.

###### 

KEGG pathways enriched in the 144 genes of the yellow module.

  ID         Description                               P-value        Adjusted P-value
  ---------- ----------------------------------------- -------------- ------------------
  hsa04110   Cell cycle                                5.22×10^−18^   3.13×10^−17^
  hsa04114   Oocyte meiosis                            2.17×10^−9^    6.50×10^−9^
  hsa04115   p53 signaling pathway                     2.46×10^−5^    4.91×10^−5^
  hsa04914   Progesterone-mediated oocyte maturation   9.19×10^−5^    1.38×10^−4^

p53, tumor protein p53. Adjusted P-value: Using multiple comparisons in a general linear model analysis of variance, the adjusted P-value indicates which factor level comparisons within a family of comparisons (hypothesis tests) are significantly different.

###### 

Top 10 hub genes in the yellow module.

  Dataset    Gene name   Coefficient   P-value   *k*~Total~   *k*~Within~
  ---------- ----------- ------------- --------- ------------ -------------
  GSE2034    CCNB2       0.3640        0.0003    14.7998      12.4392
             PRC1        0.3868        0.0005    12.9603      11.3677
             UBE2C       0.4281        0.0006    14.1236      11.2433
             ASPM        0.3442        0.0002    12.9467      10.9328
             CDC20       0.2339        0.0065    14.6847      10.7527
             FOXM1       0.1988        0.0168    13.7352      10.7131
             CEP55       0.3691        0.0004    12.6988      10.6131
             KIF4A       0.2648        0.0217    12.1095      10.3165
             NUSAP1      0.3931        0.0012    11.7988      10.2885
             PTTG1       0.4027        0.0019    12.4981      10.2449
  GSE25066   CCNB2       0.323932      0.3239    0.0006       9.4109
             PRC1        0.276034      0.2760    0.0023       6.6109
             UBE2C       0.381925      0.3819    0.0003       6.1036
             ASPM        0.207911      0.2079    0.0031       4.9210
             CDC20       0.329027      0.3290    0.0000       8.5936
             FOXM1       0.170967      0.1710    0.0091       5.9345
             CEP55       0.304415      0.3044    0.0002       6.3694
             KIF4A       0.568168      0.5682    0.0001       3.1945
             NUSAP1      0.270014      0.2700    0.0061       6.7332
             PTTG1       0.791755      0.7918    0.0000       4.0029
